云南地区非小细胞肺癌患者外周血EGFR基因突变与临床病理特征的关系
发布时间：2018-11-28 15:44
【摘要】：目的探讨云南地区非小细胞肺癌外周血中表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变及与临床病理特征的关系,为该地区的肺癌个体化靶向治疗奠定基础。方法应用突变扩增阻滞系统(amplification refractory mutation system,ARMS)检测非小细胞肺癌(non-small cell lung cancer,NSCLC)外周血中EGFR基因第18、19、20及2l外显子突变情况,统计分析各类突变与患者临床病理特征的相关性。结果在364例患者中,EGFR基因突变者93例(25.5%)。其中EGFR 18 G719X突变占3.2%(3/93),EGFR 19缺失突变占48.4%(45/93),EGFR 20 S768I、T790M、20ins突变分别占3.2%(3/93)、2.2%(2/93)、3.2%(3/93),EGFR 21 L858R、L861Q突变分别占26.9%(25/93)、1.1%(1/93);双突变比例占11.8%,其中3例样本3.2%(3/93)存在G719X、S768I双突变,4例样本4.3%(4/93)存在19Del、T790M双突变,1例样本1.1%(1/93)存在19Del、L858R双突变,1例样本1.1%(1/93)存在L858R、S768I双突变,2例样本2.2%(2/93)存在S768I、T790M双突变。EGFR基因突变与患者性别、临床分期、组织学类型相关(P0.005),而与患者年龄、是否吸烟无明显相关(P0.05)。结论云南地区ⅢB~Ⅳ期NSCLC患者外周血中,女性腺癌突变率较高,且该地区NSCLC患者外周血EGFR基因突变存在外显子19缺失突变为主及双突变率较高的特征。使用ARMS技术检测NSCLC患者外周血EGFR基因突变可为临床使用EGFR-TKIs提供准确的指导。
[Abstract]:Objective to investigate the mutation of epidermal growth factor receptor (epidermal growth factor receptor,EGFR) gene in peripheral blood of non-small cell lung cancer (NSCLC) in Yunnan and its relationship with clinicopathological features, and to lay a foundation for individualized targeted therapy of lung cancer in Yunnan. Methods mutation amplification block system (amplification refractory mutation system,ARMS) was used to detect the mutation of exon 18M19 and exon 21 of EGFR gene in peripheral blood of patients with non-small cell lung cancer (non-small cell lung cancer,NSCLC). The correlation between all kinds of mutations and clinicopathological features of patients was analyzed statistically. Results among 364 patients, 93 (25.5%) had mutation of EGFR gene. Among them, EGFR 18 G719X mutation accounted for 3.2% (3 / 93), EGFR 19 deletion mutation 48.4%) (45 / 93), EGFR 20 S768IX T790MN 20ins mutation accounted for 3.2% (3 / 93), 2.2% (2 / 93), 3.2% (3 / 93), respectively. EGFR 21 L858RV L861Q mutation accounted for 26.9% (25 / 93) and 1.1% (1 / 93), respectively. The rate of double mutation was 11.80.There were 3 cases (3 / 93) with G719XX S768I double mutation, 4 cases with 4.3% (4 / 93) with 19Delt T790M double mutation, 1 case with 1% (1 / 93) with 19Dell. The L858R double mutation was found in 1 case (1 / 93) and 2 cases (2.2% (2 / 93). The mutation of EGFR gene was associated with the patient's sex and clinical stage. Histological type was correlated (P0.005), but there was no significant correlation with age, smoking or not (P0.05). Conclusion the mutation rate of female adenocarcinoma is higher in peripheral blood of patients with stage 鈪，
本文编号：2363335
[Abstract]:Objective to investigate the mutation of epidermal growth factor receptor (epidermal growth factor receptor,EGFR) gene in peripheral blood of non-small cell lung cancer (NSCLC) in Yunnan and its relationship with clinicopathological features, and to lay a foundation for individualized targeted therapy of lung cancer in Yunnan. Methods mutation amplification block system (amplification refractory mutation system,ARMS) was used to detect the mutation of exon 18M19 and exon 21 of EGFR gene in peripheral blood of patients with non-small cell lung cancer (non-small cell lung cancer,NSCLC). The correlation between all kinds of mutations and clinicopathological features of patients was analyzed statistically. Results among 364 patients, 93 (25.5%) had mutation of EGFR gene. Among them, EGFR 18 G719X mutation accounted for 3.2% (3 / 93), EGFR 19 deletion mutation 48.4%) (45 / 93), EGFR 20 S768IX T790MN 20ins mutation accounted for 3.2% (3 / 93), 2.2% (2 / 93), 3.2% (3 / 93), respectively. EGFR 21 L858RV L861Q mutation accounted for 26.9% (25 / 93) and 1.1% (1 / 93), respectively. The rate of double mutation was 11.80.There were 3 cases (3 / 93) with G719XX S768I double mutation, 4 cases with 4.3% (4 / 93) with 19Delt T790M double mutation, 1 case with 1% (1 / 93) with 19Dell. The L858R double mutation was found in 1 case (1 / 93) and 2 cases (2.2% (2 / 93). The mutation of EGFR gene was associated with the patient's sex and clinical stage. Histological type was correlated (P0.005), but there was no significant correlation with age, smoking or not (P0.05). Conclusion the mutation rate of female adenocarcinoma is higher in peripheral blood of patients with stage 鈪，
本文编号：2363335
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2363335.html
